The association between transforming growth factor β3 polymorphisms and left ventricular structure in hypertensive subjects

Clinica Chimica Acta

Volumn 411, Issue 7-8, 2010, Pages 558-562

  Hu, Bang Chuan ^a,c   Li, Li ^b,c   Sun, Ren Hua ^a   Gao, Ping Jin ^c   Zhu, Ding Liang ^c   Wang, Ji Guang ^c   Chu, Shao Li ^c  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b ZHEJIANG HOSPITAL   (China)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Genetic polymorphism; Hypertension; Left ventricular structure; Transforming growth factor

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BENAZAPRIL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; NIFEDIPINE; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA3; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; URIC ACID; VALSARTAN;

ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; BODY WEIGHT; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DNA POLYMORPHISM; GENETIC POLYMORPHISM; GENOTYPE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE VOLUME; HOMOZYGOSITY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ECHOCARDIOGRAPHY; FEMALE; GENOTYPE; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TRANSFORMING GROWTH FACTOR BETA3; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77649186285     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.01.014     Document Type: Article

References (31)

1. Koren M.J., Ulin R.J., Koren A.T., Laragh J.H., Devereux R.B. Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens 2002, 15:1021-1028.
2. Verdecchia P., Schillaci G., Borgioni C., et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998, 97:48-54.
3. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322:1561-1566.
4. Verdecchia P., Porcellati C. Defining normal ambulatory blood pressure in relation to target organ damage and prognosis. Am J Hypertens 1993, 6:207S-210S.
5. Post W.S., Larson M.G., Myers R.H., Galderisi M., Levy D. Heritability of left ventricular mass: the Framingham Heart Study. Hypertension 1997, 30:1025-1028.
6. Arnett D.K., Hong Y., Bella J.N., et al. Sibling correlation of left ventricular mass and geometry in hypertensive African Americans and Whites: the HyperGEN study. Hypertension Genetic Epidemiology Network. Am J Hypertens 2001, 14:1226-1230.
7. Calderone A., Takahashi N., Izzo N.J., Thaik C.M., Colucci W.S. Pressure- and volume-induced left ventricular hypertrophies are associated with distinct myocyte phenotypes and differential induction of peptide growth factor mRNAs. Circulation 1995, 92:2385-2390.
8. Li J.M., Brooks G. Differential protein expression and subcellular distribution of TGFbeta1, beta2 and beta3 in cardiomyocytes during pressure overload-induced hypertrophy. J Mol Cell Cardiol 1997, 29:2213-2224.
9. Deten A., Hölzl A., Leicht M., Barth W., Zimmer H.G. Changes in extracellular matrix and in transforming growth factor beta isoforms after coronary artery ligation in rats. J Mol Cell Cardiol 2001, 33:1191-1207.
10. Yamada Y., Miyauchi A., Goto J., et al. Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J Bone Miner Res 1998, 13:1569-1576.
11. Yokota M., Ichihara S., Lin T.L., Nakashima N., Yamada Y. Association of a T29->C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000, 101:2783-2787.
12. Argano C., Duro G., Corrao S., et al. Transforming growth factor beta1 T29C gene polymorphism and hypertension: relationship with cardiovascular and renal damage. Blood Press 2008, 17:220-226.
13. Xu H.Y., Hou X.W., Wang L.F., Wang N.F., Xu J. Association between transforming growth factor beta1 polymorphisms and left ventricle hypertrophy in essential hypertensive subjects. Mol Cell Biochem 2010, 335:13-17.
14. Devereux R.B., Lutas E.M., Casale P.N., et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984, 4:1222-1230.
15. Chen J., Germer S., Higuchi R., Berkowitz G., Godbold J., Wetmur J.G. Kinetic polymerase chain reaction on pooled DNA: a high-throughput, high-efficiency alternative in genetic epidemiological studies. Cancer Epidemiol Biomarkers Prev 2002, 11:131-136.
16. Schultz J.J., Witt S.A., Glascock B.J., et al. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 2002, 109:787-796.
17. Seeland U., Haeuseler C., Hinrichs R., et al. Myocardial fibrosis in transforming growth factor-beta(1) (TGF-beta(1)) transgenic mice is associated with inhibition of interstitial collagenase. Eur J Clin Invest 2002, 32:295-303.
18. Kaartinen V., Voncken J.W., Shuler C., et al. Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat Genet 1995, 11:415-421.
19. Bjørnstad J.L., Neverdal N.O., Vengen O.A., et al. Alterations in circulating activin A, GDF-15, TGF-beta3 and MMP-2, -3, and -9 during one year of left ventricular reverse remodelling in patients operated for severe aortic stenosis. Eur J Heart Fail 2008, 10:1201-1207.
20. Beffagna G., Occhi G., Nava A., et al. Regulatory mutations in transforming growth factor-beta3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1. Cardiovasc Res 2005, 65:366-373.
21. Hu B.C., Chu S.L., Wang G.L., Gao P.J., Zhu D.L., Wang J.G. Association between genetic variation in transforming growth factors beta1 and beta3 and renal dysfunction in non-diabetic Chinese. Clin Exp Hypertens 2008, 30:121-131.
22. Kruit A., Grutters J.C., Ruven H.J., et al. Transforming growth factor-beta gene polymorphisms in sarcoidosis patients with and without fibrosis. Chest 2006, 129:1584-1591.
23. Frank J., Roux J., Kawakatsu H., et al. Transforming growth factor-beta1 decreases expression of the epithelial sodium channel alphaENaC and alveolar epithelial vectorial sodium and fluid transport via an ERK1/2-dependent mechanism. J Biol Chem 2003, 278:43939-43950.
24. Chaturvedi K., Sarkar D.K. Role of protein kinase C-Ras-MAPK p44/42 in ethanol and transforming growth factor-beta3-induced basic fibroblast growth factor release from folliculostellate cells. J Pharmacol Exp Ther 2005, 314:1346-1352.
25. Sarkar D.K., Boyadjieva N.I. Ethanol alters production and secretion of estrogen-regulated growth factors that control prolactin-secreting tumors in the pituitary. Alcohol Clin Exp Res 2007, 31:2101-2105.
26. Thomas G., Haider B., Oldewurtel H.A., Lyons M.M., Yeh C.K., Regan T.J. Progression of myocardial abnormalities in experimental alcoholism. Am J Cardiol 1980, 46:233-241.
27. Manolio T.A., Levy D., Garrison R.J., Castelli W.P., Kannel W.B. Relation of alcohol intake to left ventricular mass: the Framingham Study. J Am Coll Cardiol 1991, 17:717-721.
28. Vriz O., Piccolo D., Cozzutti E., et al. The effects of alcohol consumption on ambulatory blood pressure and target organs in subjects with borderline to mild hypertension. HARVEST Study Group. Am J Hypertens 1998, 11:230-234.
29. Yamada Y., Fujisawa M., Ando F., Niino N., Tanaka M., Shimokata H. Association of a polymorphism of the transforming growth factor-beta1 gene with blood pressure in Japanese individuals. J Hum Genet 2002, 47:243-248.
30. Koch W., Hoppmann P., Mueller J.C., Schömig A., Kastrati A. Association of transforming growth factor-beta1 gene polymorphisms with myocardial infarction in patients with angiographically proven coronary heart disease. Arterioscler Thromb Vasc Biol 2006, 26:1114-1119.
31. Sie M.P., Uitterlinden A.G., Bos M.J., et al. TGF-beta 1 polymorphisms and risk of myocardial infarction and stroke: the Rotterdam Study. Stroke 2006, 37:2667-2671.